Covered recipient · General Payments record
DAVID N OUBRE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$31,417.70
167 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $17,811.50 | 8 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,388.00 | 3 |
| Food and Beverage | $2,651.84 | 152 |
| Honoraria | $1,750.00 | 1 |
| Travel and Lodging | $816.36 | 3 |
By paying entity
PY2020 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 167 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID N OUBRE
NPI 1104883305 · CMS profile ID 321762
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
HAMMOND, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 167 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104883305?year=2020&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID N OUBRE, NPI 1104883305, CMS profile ID 321762. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 167 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104883305?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). DAVID N OUBRE, NPI 1104883305, CMS profile ID 321762. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 167 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104883305?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- DAVID N OUBRE, NPI 1104883305, CMS profile ID 321762, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 167 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1104883305?year=2020&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
167 matching records · $31,417.70 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 167.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $17.21 | 06/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719105189 | CMS |
| Puma Biotechnology, Inc. | $13.75 | 06/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750541345 | CMS |
| Secura Bio, Inc. | $13.25 | 06/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 733547779 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.28 | 06/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747325545 | CMS |
| Seagen Inc. | $19.66 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732431261 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.50 | 05/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736291085 | CMS |
| Novartis Pharmaceuticals Corporation | $24.16 | 05/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726058741 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.45 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727850405 | CMS |
| PFIZER INC. | $15.48 | 05/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743543513 | CMS |
| Incyte Corporation | $15.01 | 05/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745810005 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.18 | 05/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749516185 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.11 | 05/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735770213 | CMS |
| Seagen Inc. | $14.50 | 05/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732431251 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $13.85 | 05/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713617837 | CMS |
| Dova Pharmaceuticals | $13.92 | 05/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752352481 | CMS |
| Secura Bio, Inc. | $13.07 | 05/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 733547837 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $17.49 | 05/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713638049 | CMS |
| Blueprint Medicines Corporation | $12.93 | 04/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750716603 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $18.37 | 04/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725665405 | CMS |
| AbbVie Inc. | $19.20 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722062525 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $11.77 | 04/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713619179 | CMS |
| Coherus Biosciences Inc. | $18.23 | 04/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750864093 | CMS |
| Dova Pharmaceuticals | $15.96 | 04/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752352345 | CMS |
| Amgen Inc. | $19.94 | 04/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740995919 | CMS |
| Celgene Corporation | $16.67 | 04/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727850437 | CMS |
| Celgene Corporation | $16.73 | 04/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727850441 | CMS |
| PFIZER INC. | $15.58 | 04/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743521689 | CMS |
| Lexicon Pharmaceuticals, Inc. | $17.60 | 04/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751838341 | CMS |
| Blueprint Medicines Corporation | $14.43 | 03/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750716595 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.32 | 03/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727850399 | CMS |
| Merck Sharp & Dohme Corporation | $17.66 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747653903 | CMS |
| Celgene Corporation | $21.11 | 03/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727850435 | CMS |
| PFIZER INC. | $11.12 | 03/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743570893 | CMS |
| Daiichi Sankyo Inc. | $16.52 | 03/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739487503 | CMS |
| Novartis Pharmaceuticals Corporation | $15.20 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726058735 | CMS |
| Jazz Pharmaceuticals Inc. | $19.76 | 03/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744448155 | CMS |
| Karyopharm Therapeutics Inc. | $16.03 | 03/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751731257 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $20.63 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713636773 | CMS |
| Verastem, Inc. | $16.18 | 02/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750487609 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 02/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727850383 | CMS |
| Alexion Pharmaceuticals, Inc. | $12.52 | 02/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726635543 | CMS |
| Incyte Corporation | $15.50 | 02/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745809933 | CMS |
| Daiichi Sankyo Inc. | $6,826.50 | 02/13/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739473617 | CMS |
| Novartis Pharmaceuticals Corporation | $17.57 | 02/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726058731 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.82 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736172887 | CMS |
| Janssen Biotech, Inc. | $15.88 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719105193 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $19.61 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725660185 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.47 | 02/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749458475 | CMS |
| Daiichi Sankyo Inc. | $75.00 | 02/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739475435 | CMS |
| Daiichi Sankyo Inc. | $50.00 | 02/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739478317 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,000.00 | 1 |
| PY2025 | Principal investigator | $250,356.91 | 41 |
| PY2024 | Recipient | $1,118.04 | 1 |
| PY2024 | Principal investigator | $195,442.52 | 39 |
| PY2023 | Recipient | $19,675.45 | 3 |
| PY2023 | Principal investigator | $132,488.19 | 39 |
| PY2022 | Recipient | $22.00 | 1 |
| PY2022 | Principal investigator | $79,561.90 | 36 |
| PY2021 | Recipient | $2,540.00 | 4 |
| PY2021 | Principal investigator | $128,754.64 | 38 |
| PY2020 | Recipient | $8,022.35 | 1 |
| PY2020 | Principal investigator | $297,002.22 | 29 |
| PY2019 | Recipient | $53,131.54 | 1 |
| PY2019 | Principal investigator | $200,942.12 | 48 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
42 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | E.R. Squibb & Sons, L.L.C. | $1,000.00 | 12/03/2025 | Covered Recipient Physician | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1236002081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298827 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $28,555.00 | 09/12/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer | No dispute reported | 06/30/2026 | 1185543422 |
| Principal investigator 1 | ABBVIE INC. | $3,650.00 | 08/15/2025 | Non-covered Recipient Entity QCCA NETWORK LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202504963 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $669.65 | 08/08/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1235994587 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $5,165.00 | 07/29/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190329209 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,350.00 | 07/22/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190333090 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,668.00 | 06/17/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190326064 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 06/12/2025 | Non-covered Recipient Entity QCCA NETWORK LLC | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | No dispute reported | 06/30/2026 | 1202491105 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,550.00 | 05/30/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185543429 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $11,074.00 | 05/30/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190326062 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,902.00 | 05/30/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331387 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 05/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 05/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299362 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $7,440.00 | 05/28/2025 | Non-covered Recipient Entity Exigent Research Llc | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236531150 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 05/09/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299424 |
| Principal investigator 1 | GENZYME CORPORATION | $31,810.00 | 05/05/2025 | Non-covered Recipient Entity Exigent Research Llc | A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226109187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 04/30/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299476 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298376 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,391.91 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175298553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299063 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299126 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.40 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299181 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299579 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.88 | 04/28/2025 | Non-covered Recipient Entity Exigent Rsrch Llc | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) | No dispute reported | 06/30/2026 | 1175299587 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $2,641.21 | 04/28/2025 | Non-covered Recipient Entity Oncare Alliance, Llc | A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther | No dispute reported | 06/30/2026 | 1236530821 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,668.00 | 04/22/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190326066 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,941.00 | 04/22/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331385 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $7,815.00 | 03/25/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190326060 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $960.00 | 03/25/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190338620 |
| Principal investigator 1 | BeiGene USA, Inc. | $19,065.00 | 03/11/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190322490 |
| Principal investigator 1 | AstraZeneca UK Limited | $3,733.63 | 02/26/2025 | Non-covered Recipient Entity EXIGENT RESEARCH | an observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD | No dispute reported | 06/30/2026 | 1185543426 |
| Principal investigator 1 | BeiGene USA, Inc. | $2,133.00 | 02/20/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190322488 |
| Principal investigator 1 | Celgene Corporation | $5,450.00 | 02/19/2025 | Non-covered Recipient Entity Oncare Alliance, Llc | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. | No dispute reported | 06/30/2026 | 1222306565 |
| Principal investigator 1 | Genentech, Inc. | $1,250.00 | 02/05/2025 | Non-covered Recipient Entity PONTCHARTRAIN CANCER CENTER | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211638761 |
| Principal investigator 1 | Genentech, Inc. | $1,400.00 | 02/05/2025 | Non-covered Recipient Entity PONTCHARTRAIN CANCER CENTER | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211638766 |
| Principal investigator 1 | Genentech, Inc. | $1,728.00 | 02/05/2025 | Non-covered Recipient Entity PONTCHARTRAIN CANCER CENTER | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211638770 |
| Principal investigator 1 | Genentech, Inc. | $1,750.00 | 02/05/2025 | Non-covered Recipient Entity PONTCHARTRAIN CANCER CENTER | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211638774 |
| Principal investigator 1 | BeiGene USA, Inc. | $1,200.00 | 01/28/2025 | Non-covered Recipient Entity Pontchartrain Cancer Center | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190322486 |
| Principal investigator 1 | Eli Lilly and Company | $279.52 | 01/09/2025 | Non-covered Recipient Entity QCCA NETWORK, LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187888336 |
| Principal investigator 1 | Eli Lilly and Company | $75,667.00 | 01/07/2025 | Non-covered Recipient Entity QCCA NETWORK, LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187888326 |